Diabetes patients taking GLP-1 inhibitors were 41% less likely to develop heart failure compared with those on other glucose-lowering medications, a study indicated. Researchers also found the patients on GLP-1 inhibitors had a 44% lower risk of all-cause hospitalization and an 80% lower risk of all-cause mortality than those not on such medications. The findings were presented at the American College of Cardiology meeting.
GLP-1 inhibitors may curb heart failure risk in diabetes
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|